Evonik Evonik

X
[{"orgOrder":0,"company":"ViaDerma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViaDerma Announces Intent to Launch a New Minoxidil Hair Regrowth Product","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"ViaDerma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViaDerma Announces FDA Registration Application Update & Brand Name for New Hair Regrowth Product","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by ViaDerma

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Nupelo (minoxidil) is a vasodilator, meaning it widens the blood vessels to deliver more oxygen-rich blood to the hair follicles. It also helps increase the size of hair follicles, which promotes the growth of thicker, stronger hairs.

            Lead Product(s): Minoxidil

            Therapeutic Area: Dermatology Product Name: Nupelo

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 16, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Minoxidil may act as an 'epidermal growth factor' on matrix cells delaying their aging, thus prolonging the duration of the anagen phase via the activation of the beta-catenin pathway.

            Lead Product(s): Minoxidil

            Therapeutic Area: Dermatology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 08, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY